• Home
• About
  • Overview
  • Management Team
  • Board of Directors
  • Clinical Advisory Board
  • Business Development
• Science
  • Overview
  • Publications
• Therapeutic Targets
  • Pipeline
  • Wound Healing
  • Myocardial Infarction
  • Stroke
  • Cartilage / Bone
• Contact Us
• Download Our Corporate Profile (PDF)

Management Team

Barry Dickman

Mr. Dickman joined the Board of Directors of GliaMed in June 2008 as the representative of Quantum Technology Partners. Currently Mr. Dickman is Chairman and CEO of the GliaMed and is the founder and managing general partner of Quantum. In addition to GliaMed, Mr. Dickman is responsible for Quantum’s investments in BiPar Sciences, an oncology company acquired by sanofi-aventis in 2Q2009; Vaxart, an oral vaccine delivery company; IMI Devices, developing an implantable device for treating blindness; Peri-Ness, a company developing a therapy for male infertility; and Corium, a transdermal delivery technology and product company.

Prior to founding Quantum, Mr. Dickman spent more than 25 years in technology and executive management positions. During this time he was founder and/or CEO of three technology companies which were acquired or went public. He also held senior management positions at Autodesk and Exxon Enterprise and has consulted for major corporations including News Corporation, HBO, DEC, Eastman Kodak and Adobe Systems.

David E. Weinstein, M.D., Ph.D.

Dr. Weinstein is the Founder and Chief Scientific Officer of GliaMed, and was formerly a professor in the Departments of Neuroscience and Pathology at the Albert Einstein College of Medicine. He is an internationally recognized expert in the areas of multiple sclerosis, brain tumor research and spinal cord and nerve regeneration, and has served as a consultant and advisor to both the NIH and the WHO, as well as to a number of scientific research organizations including the Children’s Brain Tumor Foundation, the Christopher Reeves Paralysis Foundation, the Paralyzed Veterans of America/Spinal Cord Research Foundation and the National Multiple Sclerosis Foundation.

Judith I. Blakemore

Ms. Blakemore has been working for GliaMed since October 2008, and is presently leading the company’s drug development and business development activities. She was formerly COO of Onyx Pharmaceuticals, where she was a member of the joint research committee that oversaw the preclinical and early clinical development of Nexavar® president of XTL Biopharma Ltd., a company engaged in the discovery and development of antiviral therapeutics; and vice president of biological therapeutics development at Cetus Corporation, where she was responsible for managing the development of Cetus’ biotechnology products including Betaseron® beta interferon and Proleukin® IL-2. Over the past 15 years, Ms. Blakemore has served as a key consultant for more than 40 biotech and specialty pharma companies, many of them at the start-up phase. She also serves on the advisory board of CM Capital Investments, an Australian venture capital firm.

John McCartney, Ph.D.

John McCartney joined GliaMed in April 2009 as Senior Director of Project Management to oversee GliaMed’s internal and external drug development activities. Dr. McCartney has over 20 years of drug development and project management experience, working previously with EPIX Pharmaceuticals, Point Therapeutics, Cystic Fibrosis Foundation Therapeutics and Curis/Creative BioMolecules. Dr. McCartney has led both preclinical and clinical development teams in multiple therapeutic areas, including orthopedic, urologic and vascular tissue repair, as well as oncology and pulmonary diseases. Dr. McCartney received his Ph.D. from Duke University and postdoctoral training at the Massachusetts Institute of Technology.